Harris R E, Namboodiri K K, Farrar W B
Comprehensive Cancer Center, Ohio State University, Columbus, USA.
Epidemiology. 1996 Mar;7(2):203-5. doi: 10.1097/00001648-199603000-00017.
We examined the association of nonsteroidal antiinflammatory drugs and breast cancer risk in a case-control study of 511 breast cancer patients and 1,534 population control subjects. The relative risk of breast cancer was reduced in women using these compounds at least 3 times per week for > or = 1 year [odds ratio (OR) = 0.66; 95% confidence interval (CI) = 0.52-0.83]. Odds ratios were similar for use of ibuprofen (0.57) or aspirin per se (0.69). Breast cancer risk declined with increasing exposure, and the greatest risk reduction (40%; odds ratio = 0.60; 95% CI = 0.40-0.91) occurred at the highest level of use (daily intake for > or = 5 years). These results indicate that nonsteroidal antiinflammatory drugs may have chemopreventive potential against the development of breast cancer.
在一项针对511名乳腺癌患者和1534名人群对照受试者的病例对照研究中,我们考察了非甾体抗炎药与乳腺癌风险之间的关联。每周至少使用这些化合物3次且持续≥1年的女性,患乳腺癌的相对风险降低[比值比(OR)=0.66;95%置信区间(CI)=0.52 - 0.83]。使用布洛芬(0.57)或阿司匹林本身(0.69)的比值比相似。乳腺癌风险随暴露量增加而降低,在最高使用水平(每日服用≥5年)时风险降低幅度最大(40%;比值比=0.60;95%CI=0.40 - 0.91)。这些结果表明,非甾体抗炎药可能对乳腺癌的发生具有化学预防潜力。